These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7815460)

  • 21. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
    Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
    Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
    Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
    Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
    Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
    el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
    Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
    Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage.
    Kurz T; Gustafsson B; Brunk UT
    FEBS J; 2006 Jul; 273(13):3106-17. PubMed ID: 16762036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates.
    Konorev EA; Kennedy MC; Kalyanaraman B
    Arch Biochem Biophys; 1999 Aug; 368(2):421-8. PubMed ID: 10441396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
    Zhang J; Clark JR; Herman EH; Ferrans VJ
    J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
    de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
    Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
    Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
    Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.
    Hoyes KP; Hider RC; Porter JB
    Cancer Res; 1992 Sep; 52(17):4591-9. PubMed ID: 1511427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective effect of arabic gum against cardiotoxicity induced by doxorubicin in mice: a possible mechanism of protection.
    Abd-Allah AR; Al-Majed AA; Mostafa AM; Al-Shabanah OA; Din AG; Nagi MN
    J Biochem Mol Toxicol; 2002; 16(5):254-9. PubMed ID: 12439867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
    Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
    Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
    Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
    Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
    Kaiserová H; den Hartog GJ; Simůnek T; Schröterová L; Kvasnicková E; Bast A
    Br J Pharmacol; 2006 Dec; 149(7):920-30. PubMed ID: 17031387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
    Xu X; Sutak R; Richardson DR
    Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.